Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/000884

International filing date:

12 January 2005 (12.01.2005)

Document type:

Certified copy of priority document

Document details:

Country/Office: US

Number:

60/535,908

Filing date:

12 January 2004 (12.01.2004)

Date of receipt at the International Bureau: 21 February 2005 (21.02.2005)


Remark:

Priority document submitted or transmitted to the International Bureau in

compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE ALL THE PRESENCE OF THE PRESENCE OF THE PROPERTY OF THE PR

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 07, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/535,908

FILING DATE: January 12, 2004 RELATED PCT APPLICATION NUMBER: PCT/US05/00884

Certified by

Under Secretary of Commerce for Intellectual Property and Director of the United States

Patent and Trademark Office

NO. 751

Provisional Application Cover Sheet

Address to: Washington, DC 20231

2:31PM

Express Mail #: BR519392846US

This is a request for filing a PROVISIONAL APPLICATION under 37 C.F.R. § 1.53(b)(2).

Do	ocket Number: Q3399	Type this t	e plus sign (+) insido	+
Inventor(s)/Appl	icant(s)			
Last Name	Pirat Name	Middle	Residance (City and ei Foreign Country)	ther Stats or
St. 14	Steven	- Industr	Berwyn, PA	
Siegol	1 - 1 - 1 - 1		Philadelphia, PA	
Winey	Karen		- Intraconting, - A	
Title of the Inves	ntion (280 Characters Maximu	עה)		
A Long-Term Biodegrada	ble Pormulation for Risperido	ne and 9-oh-ris	peridone	
Correspondence	Address			
University of Pennsylvani			•	
Conter For Technology T		•		·
3160 Chestmut Street	i		•	1
Suite 200	:			
Built 200	. :			
City: Philadelphia	State: Pendaytvania Zip	(>ode: 19104 -	6283 Country: US	
	stion Parts (check all that app			
[X] Specification Numb	er of pages: 16 [] Sme	Bnity Statem	ent	
[X] Specification (4000)	io il omi	u		
[] Drawing(s) Numb	er of sheets [] Othe	(apecify)		
Method of Payer	nent (check one)			
(1 Our Check No.	is enclosed to cover the Prov	is: onal filing for	8. A Provisional	
duplicate copy of this she	ot is enclosed.		Filing Fee	
dubucano copy or time our	•		Amount (8)	\$ 80.00
(V) The Commissioner	is hereby authorized to charge	filing fees and	credit	
Dennis Agount No. 13	2489. A diplicate copy of thi	a shoet is enclos	od.	1
Deposit Account No. 13	!			1
() Payment by credit can	rd. Form PIO-2028 is attached	d.		
		كندخووو و		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No
[] Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted

Typed or Printed Name: Steven Sieg

[] Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

PROVISIONAL APPLICATION SUBMISSION TO USPTO - CONTENTS PAGE

Penn Docket Number:

Q3399

First-named Inventor:

Siegel

Submission Date

1/12/04

Prepared by

Matt Thomas

CONTENTS LISTED IN ORDER:

Page Nos.	Descriptor
1	This Page
2-3	Disclosure Summary
4-16	Risperidone Figures and Charts

Total Number of Pages : 16

Siegel, S. J. et. al. Risperidone and 9-OH Risperidone

Brief Summary

We have devised a long-term delivery formulation for the antipsychotic agent risperidone and its active metabolite 9-oh-Risperidone. Risperidone is currently in use for the treatment schizophrenia, bipolar disorder, Alzheimer's Disease, psychotic depression, and other mental conditions that cause confusion, disorganization and psychosis. The current formulation would allow for incorporation of both risperidone and 9-oh-risperidone into multiple delivery platforms including:

- 1. Surgically implantable formulation: this method would be best suited for the treatment of chronic conditions listed above.
- Incorporation into nanoparticles for stealth long-term delivery through the GI tract.
 As PLGA loaded nanoparticles are delivered across the intestinal mucosa, active drug would evade first pass metabolism. Additionally, this method could deliver antipsychotic activity for one-week interval.
- 3. The use of 9-oh-risperdidone is included since this molecule has a hydroxyl functional group that allows for ester bond formation, and creation of pro-drug polymers that will deliver improved controlled release as compared to physical mixtures.

Stage of development

We have tested multiple compounds in PLGA delivery systems in vitro. These studies indicate that every drug results in a different pattern of release. Risperidone and 9-oh risperidone result in a highly stable drug-polymer matrix with kinetics that approach steady state over the delivery interval, even with a polymer (50:50 PLGA) that traditionally yields a high degree of drug dumping after an initial lag. Additionally, we are able to make nanoparticles with PLGA and incorporate drugs into these particles for oral delivery systems.

Applications/Commercial use

The commercial application of this technology is related to treatment of schizophrenia, bipolar disorder, Alzheimer's Disease, psychotic depression, and other mental conditions that cause confusion, disorganization and psychosis.

Closest know similar technology


Current formulations of risperidone include daily oral formulations and biweekly PLGA based microspheres (Risperidone Consta). There are no pro-drug polymers utilizing 9-oh risperidone in use, or that we are aware of in development.


Differences / advantages


The major advantages to a long-term polymer based delivery system for this drug include:


Steady state delivery over weeks to months, avoiding peaks and troughs from oral dosing

- Lower dosing through avoidance of first pass metabolism resulting in less systemic toxicity.
- Greater ease of administration with resulting in improved adherence as compared to current oral medications.
- Long term implants t offer a degree of treatment adherence (annual) and resulting improvement that is not currently available in any psychiatric medication.











		Avg (P1, P2, P3) Conc -2.70343E-06 0.000754238 0.000154253 0.001055153 0.001055153 0.001055153 0.001055155 0.001055153 0.001052164 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213 0.002647213
P3C ABS	0.003 0.001 0.005 0.005 0.015 0.015 0.019 0.030 0.030 0.030 0.030 0.048 0.068 0.068	P3C Conc 0.00047 0.00047 0.00047 0.000557 0.00057 0.00071 0.001755 0.001755 0.001755 0.001755 0.001755 0.001755 0.001755 0.001755 0.001755
P2C F	0,005 0,017 0,019 0,031 0,046 0,056 0,066 0,066 0,068 0,089 0,089 0,103 0,119 0,119 0,147	Conc.
	0.000 0.010 0.010 0.010 0.026 0.027 0.039 0.039 0.055 0.055 0.055 0.056	10 Conc Conc Conc Conc Conc Conc Conc Conc
beflicient P1C ABS	0.0014 0.003 0.006 0.0000 0.00	C C C C C C C C C C C C C C C C C C C
Pos Control Carection Coefficient P1C ABS	o c a r c e c c z z z z z z z z z z z z z z z z	CONCENTRATION Day
ABSORBANCE Day		9, P2, P3) 0,000470397 0,000470397 0,000459046 0,000655018 0,000655018 0,0001416599 0,001416599 0,001416599 0,0012214112 0,001252412 0,001252412 0,001252412 0,001252412 0,001252412 0,001252412 0,001252412 0,001252412 0,001252515 0,001252515 0,001252515 0,001252515 0,001252515 0,001252515 0,001252515 0,001252515
		600000000000000000000000000000000000000
je S	0.382 0.427 0.459 0.459 0.454 0.454 0.457 0.451 0.451 0.451 0.452 0.453 0.453 0.453 0.453 0.453	Pos Control Conc 0.015633416 0.01764234 0.01764234 0.01896182 0.01896183 0.01896183 0.01896183 0.01896133 0.01896133 0.01886779 0.01886779 0.01886779 0.01886779 0.01886779 0.01886779 0.01886778 0.01886778
	0.001 0.002 0.003 0.003 0.003 0.003 0.013 0.013 0.023 0.023 0.023 0.033	10000000000000000000000000000000000000
ABS	0.009 0.009 0.009 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003 0.003	Corc.
P2 A0S	0.004	P 551095 942985 942985 987591 111922 112198 152474 152474 176805 193025 193025 193025 193025 193025 193025 19303 193025 19302
P1	0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000	PH 15985 0008191 00081
Neg Control	2	20 20 20 20 20 20 20 20 20 20 20 20 20 2
ORBANCE	, o v * v = z z = z z z z z z z z z z z z z z z	CONCENTRATION Day 10 11 12 13 13 13 14 4 4


67.


_	_	0.255474 0.194647 0	2 0.214922952 0.255474 0.174371 0.214922952	4 -0.0081103 0.072993 -0.06894 -0.001351717	0.235199 0.	0.559611 0.194647 0.	0.80292 0.296026 0	1.107056 0.437956 0.	1.188159 1.289538	0.458232	1,431468 0,498783	.512571 0.559611	1.472019 0.397405	796431	1.958637 0.782644	32 1,330089213 1,978913 0,863747 1,390916464	35 1,451743715 2,262774, 0,904298 1,539605299	37 1,390916464 2,222222 0,843471 1,485536632	39 1,715328467 2,56691 1,147607 1,809948635	2 87 1046 4 309813	2 CIOCOCI DED 10.3	3.053528 1.390916 2.	46 2.201946472 3,154907 1,451744 2,269532306
500 mL	Corrected Day		•																				
Avg (P1, P2 P3)	Total Drug	0.235198702	0.214922952	0.282508785	0,437956204	0.498783455	0.593403623	0.70829954	1,107055961	0.843471208	0.951608543	1.012435793	1,113814544	1,147607461	1,201676129	1,228710462	1,417950798	1,668018383	1 740121384	00000000	1,918083969	2.03974047	2,188429305
os Control		7,919708029	8.832116788	9,703974047	9,480940795	9,541768045	9.480940795	9.379562044	9.460565045	9.420113544	9,440389284	9,420113544	9,622871046	9.318734793	9.278183293	9,257907543	9.298459043	962565696	0 350786704	9.99500594	9.318734793	9.298459043	9.339010543
2	Total Drug		_	0.214923	0.296026	0,3163017	0.3568532	0.3974047	1,3300892	0.458232	0.5190592				0.6407137			1.025953	4 0067007	. نـ	-	1,269262	
P2	Total Drug	0 2554745		, .	0.5798865	0.6812652	0.863747	_	1,2287105	1,3098135	1,4517437				1.8167072		_	٠.	•	•	2.7696675	7 2,9318735	
		9	21407705	2757502	4379562	49878045	1.55961071	0.66098946	76236821	76236821	B8402271	12512571	1 06650446	1,12733171	1 14760746	1 16788321	: _	•	•	-	1.77615572	1,91808597	2.12084347
ā	Total Onto	2	2		ċ	c		_	_	٠	_	_											
Mon Control		771457	0.454005707.0.2			ď		_	_	0.174371452	0.154095702	0 194547707	A 291970803	0 373073804	0.17077804	755 PALL OF 0	1117776561	0.15585170A	20000000	0.37772899	0.377128954	0.355853204	0.377128954

500 ml. Corrected Day









new ABSORB/ Neg Contr P1 P2 P3 P95 Control P5 P95 P95 P95 P95 P95 P95 P95 P95 P95	0	CONCENT Neg Corur P1 P2 P3 Poss Contrad Day Corur Coruc Coruc Coruc Coruc Ang P1, P2, P31 0 0.000716 0.00016 0.000716 0.000716 0.018347 0.000934 2 0.000578 0.000165 0.000150 0.000050 0.01857 0.0010055 4 0.000649 0.000054 0.000130 0.000059 0.018573 0.001055 9 0.00064 0.000142 0.001522 0.000152 0.011573 0.001526 11 0.0000578 0.002147 0.002449 0.001520 0.011573 0.001526 11 0.000058 0.002147 0.002449 0.00270 0.0116373 0.001526 11 0.0000578 0.002147 0.002449 0.00270 0.011639 0.002203 11 0.0000578 0.002147 0.002449 0.00270 0.0116499 0.002203 11 0.0000578 0.002147 0.002449 0.002490 0.011449 0.0003203 12 0.000075 0.005529 0.004899 0.005489 0.01846 0.006203 13 0.000075 0.005529 0.004899 0.005489 0.01845 0.006489 14 0.000015 0.00091 0.005529 0.005629 0.01846 0.006203 15 0.00003 0.00712 0.006512 0.005578 0.01852 0.006561 15 0.00003 0.00712 0.006512 0.005578 0.01852 0.006563 15 0.000193 0.009816 0.005539 0.018912 0.006563 15 0.001053 0.009816 0.008252 0.006357 0.018912 0.006565 14 0.001053 0.009816 0.00852 0.008439 0.018919 0.008665 14 0.001053 0.009816 0.00852 0.008439 0.018919 0.008665 15 0.001093 0.009816 0.00852 0.008439 0.018919 0.008665
	ABS ABS ABS 0.468 0.014 0.003 0.479 0.011 0.003 0.474 0.074 0.003 0.474 0.002 0.474 0.002 0.047 0.002 0.474 0.002 0.047 0.002 0.474 0.047 0.011 0.115 0.471 0.471 0.147 0.159 0.445 0.141 0.159 0.445 0.141 0.159 0.445 0.141 0.159 0.445 0.143 0.159 0.445 0.103 0.199 0.461 0.103 0.199 0.461 0.103 0.199 0.461 0.103 0.199 0.461 0.103 0.199 0.461 0.103 0.199 0.461 0.103 0.103 0.461 0.103 0.103 0.461 0.103 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.403 0.461 0.103 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.461 0.103 0.103 0.461 0.103 0.103 0.461 0.103 0.103 0.103 0.461 0.103	P3 Cont 12472 0.00 11302 0.00 11302 0.00 11302 0.00 11302 0.00 11302 0.00 11303 0.00 113
Neg Control P1 P2	ABS	P1 P1 P2
POSTORBANCE		CONCENTRATION

	75.	0.00419 0.00619	-0.00081 0.00919	-0.00181 0.01119	0.00919 0.02319	0.01919 0.03219	0.04019 0.04819	0.07119 0.07519	-0.00419 0.10819 0.11419	-0.00419 0.13219 0.11519	-0.00219 0.15919 0.13419	0.16919 0.14419	0.02181 0.17019 0.14819	-0.00219 0.19419 0.16419	-0.00019 0.19719 0.16819	-0.00119 0.19919 0.17219	-0.00219 0.20519 0.18419	-0.00019 0.20419 0.16319	0.20819 0.18819	0.20919 0.19419	021319 020119	6 -0.00419 0.21519 0.20819 0.20119	P2C	Conc Conc Conc	0.000949 0.000949 (2 0.000685277 0.001062 0.000723 0.000823413	_	Ī	0.001552	0.002531 0.002155 (0.003548 0.003247	0.005018 0.004377	0.005695826 0.005055 0.005206	0.005771 0.006148	0.007089736 0.006148 0.00596	0.007127411 0.006299 0.006751	0.00803157 0.006901 0.007504	0.00814459 0.007052 0.007542	0.008219937 0.007203 0.007693	0.008445976 0.007655 0.007681	0.008408303 0.007617 0.007843	39 0.008558996 0.007806 0.007956 0.008106917	0.00859567 0.008032 0.008107	0.008747363	0.008559 0.008795	
Corrected for Negative and Positive Control	Day								•	•	CV	d	.4	.4	¢!	• 1	• 1	• •	••	•	•	•	CONCENTRATION	Day													٠									
	Day . neg conce P1 correct P2 correct P3 corrected	٥	0.015	4 0,006 0,004 0,017 0,009 0,48	0.014 0.028 0.016	0.021 0.034 0.024	0,039 0,047 0,037	0.073 0.077 0.069	0.104 0.11 0.093	0.128 0.111 0.115	0.00	0.165 0.14	0.023	0.027 0.192 0.162 0.178			0.064 0.203 0.182 0.188	-0.009 0.204 0.163 0.189	-0.01 0.205 0.185	-0.01 0.205 0.19	44 -0.009 0.211 0.199 0.196 0.472	-0.01 0.211 0.204	CONCENT Neg Contr P1 P2 P3 Pos Control	Conc Conc Conc Conc Conc Avg (P1, P2, P3)	0 0.000716 0.00064 0.000716 0.000716 0.018347 0.000691	2 0.000753 0.000904 0.001281 0.000942 0.018799 0.001042	4 0 moses 0 moses 0 00135 0 001055 0 01879 0 001093	7 DOMPSON DIGITAL DIGITAL DIGITAL DIGITAL DIGITAL	9 0 mm0791 0 m01507 0 001997 0 00162 0 018848 0 001708	0.000753 0.002185 0.002486 0.00211	0,003466 0,003617 0,003315 0,018648	0000	18 0.000716 0.005538 0.004898 0.005048 0.018422 0.005161	0.000753 0.005631 0.005689	23 0,000678 0,006932 0,00599 0,005802 0,018422 0,006241	0.007949	0007949 0.006819 0.007422	008137 0.007045 0.007535 0.018573	32 0 00171 0 008175 0 007158 0 007648 0 018535 0 00766	984910 0 007570 0 007880 0 018498	192000 0 10761	589200 0 627800 1	0.000439 0.007874 0.007949 4	CLOCKED AND CONTRACT OF THE CO	U.UOUS/1 U.UUSBBS U.UUS/11	U.000401 U.000137

A STATE OF THE STATE OF

な のおき大き

500 ml. Corrected Day

```
P2C P3C Avg (P1C, P2C, P3C)

1 Total Drug Total Drug

0.436521681 0.474455 0.474455

0.342539638 0.531045 0.531475

0.3425391989 0.558678 0.471865

0.31005124 0.794718 0.586878 0.436521881

0.511005124 0.794718 0.586878 0.436521881

1.11494123 1.265534 1.077288 1.152614527

1.68987733 1.774224 1.677283 1.152614527

1.58987733 1.774224 1.673531 1.689877336

2.345502411 2.88558 1.077353 1.105347097

3.345502411 2.88558 1.073953 3.105347097

4.015785112 3.45068 3.75277 3.73951426

4.02728505 3.55032 3.77899 3.789343

4.22288246 3.872419 3.946255 3.789748 3.7897426

4.22288246 3.872419 3.946255 3.789741914
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     4.053458409
4.12252612
4.204151597
4.279498192
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          4.278498192 3,902765 3.
4.29833464 4,015765 4.
4,373681435 4,147642 4.
4,411354732 4,279498 4.
                                                                                         P1C
Total Drug
500 mt. Total Drug Total Drug Total Drug Total Drug Total Drug Corrected Neg Corri P1 P2 P3 Pos Corrink Ang (P1, P2 P) P3 Corrected Neg Corri P1 P2 P3 Pos Corrink Ang (P1, P2 P) 0.357896 0.357896 0.357896 0.357896 0.357339 0.545339 0.545330 0.64509 0.665022 0.557865 9.375446 0.345339 0.527446 0.345339 0.527426 9.399486 0.527470 0.045209 0.237531 0.095750 1.324319 0.052742 9.39949 0.545652 0.045753 1.32872 1.508218 1.657625 9.39648 0.546573 1.32872 1.508218 1.657625 9.324141 1.32937 11.00199 1.6 0.335789 2.34656 0.39624 2.109765 9.327112 1.2550521 1.037673 3.31325 2.644334 1.05462 9.57112 1.2550521 1.037613 9.39648 2.49574 1.09255 2.0 0.37673 3.31325 2.944334 2.200044 9.21112 1.250625 2.0 0.37613 9.397453 3.56017 3.76039 9.248794 3.656165 3.0 0.66648 4.06753 3.45943 3.77032 9.24879 3.26616 3.20018 3.56166 3.70037 9.24879 3.26616 3.70037 9.24879 3.26616 3.70037 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7613 9.24879 3.26616 3.70038 3.7616 3.70038 3.7616 9.70038 3.7616 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.26868 3.7673 9.28968 3.7673 9.28958 9.24879 3.77959 9.7673 9.7673 9.7673 9.28968 9.24879 3.77959 9.7673 9.7673 9.7673 9.28968 9.24879 4.162899 4.018936 4.327429 4.105398 9.24879 4.162899 4.1052995 3.746794 4.162899 4.018936 4.302429 4.1052999 9.24879 4.162899 4.018936 4.302429 4.1052999 9.24879 4.162899 4.018936 4.30277 4.7777 4.7777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.0777 4.077
```